Evidence map›Paper›PMID 39342050›Full record

ArticleCommunications biology2024

Nitric oxide induces the distinct invisibility phenotype of Mycobacterium tuberculosis.

Brindha Gap-Gaupool, Sarah M Glenn, Emily Milburn, Obolbek Turapov, Marialuisa Crosatti, Jennifer Hincks, Bradley Stewart, Joanna Bacon, Sharon L Kendall, Martin I Voskuil and 6 more

Abstract read
In one paragraph

Article in Communications biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Observational
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Brindha Gap-Gaupool *Leicester Tuberculosis Research Group, Department of Respiratory Sciences, University of Leicester, Leicester, LE1 9HN, UK.
Sarah M Glenn *Leicester Tuberculosis Research Group, Department of Respiratory Sciences, University of Leicester, Leicester, LE1 9HN, UK.
Emily Milburn *Leicester Tuberculosis Research Group, Department of Respiratory Sciences, University of Leicester, Leicester, LE1 9HN, UK.
Obolbek TurapovLeicester Tuberculosis Research Group, Department of Respiratory Sciences, University of Leicester, Leicester, LE1 9HN, UK.
Marialuisa CrosattiLeicester Tuberculosis Research Group, Department of Respiratory Sciences, University of Leicester, Leicester, LE1 9HN, UK.
Jennifer HincksFACS Facility Core Biotechnology Services, University of Leicester, Leicester, LE1 9HN, UK.
Bradley StewartLeicester Tuberculosis Research Group, Department of Respiratory Sciences, University of Leicester, Leicester, LE1 9HN, UK.
Joanna BaconDiscovery Group, Vaccine Development and Evaluation Centre, UK Health Security Agency, Porton Down, SP4 0JG, UK.
Sharon L KendallCentre for Endemic, Emerging and Exotic Disease, the Royal Veterinary College, Hatfield, Hertfordshire, AL9 7TA, UK.ORCID 0000-0003-3277-3035
Martin I VoskuilDepartment of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.ORCID 0000-0002-9565-7923
Olga RiabovaResearch Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia.ORCID 0000-0002-3794-6495
Natalia MonakhovaResearch Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia.ORCID 0000-0001-5448-9567
Jeffrey GreenSchool of Biosciences, University of Sheffield, Sheffield, S10 2TN, UK.
Simon J WaddellGlobal Health and Infection, Brighton and Sussex Medical School, University of Sussex, Brighton, BN1 9PX, UK. S.Waddell@bsms.ac.uk.ORCID 0000-0002-3684-9116
Vadim A MakarovResearch Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia. makarov@inbi.ras.ru.ORCID 0000-0001-8746-2694
Galina V MukamolovaLeicester Tuberculosis Research Group, Department of Respiratory Sciences, University of Leicester, Leicester, LE1 9HN, UK. gvm4@leicester.ac.uk.ORCID 0000-0001-5697-2018

Funding

DH | NIHR | Health Services Research Programme (NIHR Health Services Research Programme) NIHR203327EC | EC Seventh Framework Programm | FP7 Ideas: European Research Council (FP7-IDEAS-ERC - Specific Programme: "Ideas" Implementing the Seventh Framework Programme of the European Community for Research, Technological Development and Demonstration Activities (2007 to 2013)) 115337RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/K000330/1RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/M01116X/1RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/P001513/1RCUK | Biotechnology and Biological Sciences Research Council (BBSRC) BB/T00746X/1
6 · The paper itself

Abstract

During infection Mycobacterium tuberculosis (Mtb) forms physiologically distinct subpopulations that are recalcitrant to treatment and undetectable using standard diagnostics. These difficult to culture or differentially culturable (DC) Mtb are revealed in liquid media, their revival is often stimulated by resuscitation-promoting factors (Rpf) and prevented by Rpf inhibitors. Here, we investigated the role of nitric oxide (NO) in promoting the DC phenotype. Rpf-dependent DC Mtb were detected following infection of interferon-γ-induced macrophages capable of producing NO, but not when inducible NO synthase was inactivated. After exposure of Mtb to a new donor for sustained NO release (named NOD), the majority of viable cells were Rpf-dependent and undetectable on solid media. Gene expression analyses revealed a broad transcriptional response to NOD, including down-regulation of all five rpf genes. The DC phenotype was partially reverted by over-expression of Rpfs which promoted peptidoglycan remodelling. Thus, NO plays a central role in the generation of Rpf-dependent Mtb, with implications for improving tuberculosis diagnostics and treatments.

Indexed as

Bacterial ProteinsMycobacterium tuberculosisNitric OxidePhenotypeAnimalsCytokinesGene Expression Regulation, BacterialHumansMacrophagesMiceTuberculosisBacterial ProteinsCytokinesNitric Oxideresuscitation-promoting factor, bacteria

Identifiers

PMID39342050
PMCPMC11439070

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.